NovoCure raises fiscal 2026 revenue outlook to $710 million–$725 million after Q2 beat as NVCR shares slide
NovoCure reported fiscal 2026 second-quarter revenue of $183.6 million, up 16% year over year, and a loss that narrowed to 13 cents per share, both ahead of expectations. The company raised its full-year revenue guidance to $710 million–$725 million. However, the Phase 3 TRIDENT trial in newly diagnosed glioblastoma did not meet its primary endpoint for overall survival, fueling concerns about expansion of its core indications. Even with a CE Mark for Optune Pax in pancreatic cancer and plans to reduce costs via a redesigned LUNAR-2 trial, the stock weakened as investors focused on the clinical readout.